Which test to use to measure the anticoagulant effect of rivaroxaban: The anti-factor Xa assay

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 4, 2013, Pages 579-580

  Samama, M M ^a,b  

^a HÔTEL DIEU   (France)

^b Biomnis Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; RIVAROXABAN;

ARTICLE; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL;

ANTICOAGULANTS; FACTOR XA; HUMANS; MORPHOLINES; THIOPHENES;

EID: 84876168580     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12165     Document Type: Article

References (11)

1. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-72.
2. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012; 130: S88-9.
3. Lindhoff-Last E, Samama MM, Oertel TL, Weitz JL, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-9.
4. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Le Flem L, Rohde G, Martinoli JL, for the rivaroxaban anti-FXa chromogenic assay field trial lab. Evaluation of the anti-Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-87.
5. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimized, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (Rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078-9.
6. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, Gourmelin Y, Martinoli JL. Evaluation of the prothrombin time for measuring Rivaroxaban plasma concentrations using calibrators and controls: the results of a multicenter field trial. Clin Appl Thromb Hemost 2012; 18: 150-8.
7. Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. Thromb Haemost 2011; 9: 226-8.
8. Harenberg J, Marx S, Krämer R, Giese C, Weiss C. Determination of an international sensivitity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011; 22: 637-41.
9. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-71.
10. Mani H, Rohde G, Stratmenn G, Hesse C, Herth N, Schwers S, Perzborn E, Lindhoff-Last E. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012; 108: 191-8.
11. McGlasson DL, Kaczor DA, Krasuski RA, Campbell CL, Kostur MR, Adinaro JT. Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagul Fibrinolysis 2005; 16: 173-6.